Isothiafludine
Based on 1 Customer Validation
Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.87%
- CAS 番号: 960527-22-4
- 分子式: C18H18FN3OS2
- 分子量:375.48
-
保管条件:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | CC50 |
29 μM
Compound: NZ-4; 10
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 2 days prior to compound washout followed by compound redosing and measured after 2 days by XTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 2 days prior to compound washout followed by compound redosing and measured after 2 days by XTT assay
|
[PMID: 30594676] |
| HepG2 2.2.15 | CC50 |
50.4 μM
Compound: II-8c; NZ-4
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by MTT assay
|
[PMID: 32712535] |
| HepG2 2.2.15 | CC50 |
51.47 μM
Compound: NZ-4
|
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
|
[PMID: 27484509] |
| HepG2 2.2.15 | CC50 |
59.2 μM
Compound: II-8c; NZ-4
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
|
[PMID: 32712535] |
| HepG2 2.2.15 | IC50 |
50.4 μM
Compound: NZ-4
|
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by MTT assay
|
[PMID: 27484509] |
Isothiafludine inhibits HBV DNA replication, with an IC50 of 1.33 μM[1].
Isothiafludine (8 days) shows an IC50 (50% cytotoxicity) of 50.4 μM against HepG2.2.15 cells[1].
Isothiafludine (1.25-20 μM, 48 h) also inhibits the replication of 3TC/ETV-dual-resistant and ADV-resistant HBV mutants in virus transfected Huh7 cells[1].
Isothiafludine (10-20 μM, 8 days) decreases the levels of encapsidated HBV pgRNA in HepG2.2.15 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DHBV-infected duck model[2]
-
Dosage:25-100 mg/kg
-
Administration:p.o., for 15 days
-
Result:Inhibited DHBV DNA in the sera on day 15.
化学情報
-
CAS 番号 960527-22-4
-
性状 Solid
-
分子量 375.48
-
分子式 C18H18FN3OS2
-
Color White to off-white
-
SMILES
O=C(C1=C(CC(C)C)SC(C2=NC=CS2)=N1)NCC3=CC=C(F)C=C3
-
別名
NZ-4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
純度とドキュメンテーション
-
データシート (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)